Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Subscribe To Our Newsletter & Stay Updated
